A C&C Special Edition: heroic covid docs publish first peer-reviewed study that brings new hope for actually curing cancer instead of piling money into Moonshot rockets and launching them into space.
substack.com
I often quip about “covid miracles”— the occasional unexpected and often surprising
blessings flowing from the pandemic. This might be the biggest covid miracle of them all. Some of our heroic pandemic docs have managed to publish a
peer-reviewed study in a mainstream journal
suggesting a potentially staggering 85% benefit for cancer patients taking a combination of two cheap, safe anti-parasitic drugs: ivermectin and mebendazole. The study’s title:
“Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”
Let’s start with the disclaimers. This was
not a “gold standard” clinical trial. The 122 participants were telemedicine patients who
self-reported their status during the study period. No placebos, randomization, or double-blinding were used. The results can’t be compared to a control group that
didn’t take the ivermectin combo.
The participants were health-motivated, self-selected cancer victims who were also trying various other things at the same time, like supplements, chemo, radiation, keto diets, fasting, etc. They were all at different stages of their oncology; some with new-onset disease, some having survived 5+ years.
...
It would be one thing if the study patients had reported a
minor benefit. But the magnitude and consistency of the self‑reported “clinical benefit” signal was so large that, even through heavy noise and bias, it
still plausibly indicates a real underlying effect worth taking very seriously and testing rigorously.
At six months, fully a third (33%) of respondents remarkably reported “no current evidence of disease” (NED). 16% reported regression, and another third (36%) reported stabilized disease, for a combined and stunning “clinical benefit ratio” (CBR) of 84% (with a 95% confidence interval of 77‑90%).
...
This study is not about “this proves ivermectin + mebendazole works.” Rather, the size, internal consistency, and biological plausibility of the observed signal, in a relatively large and diverse real‑world study group, raise a
credible possibility —if not
probability— of true anticancer activity that justifies urgent, independent, randomized, controlled trials, and cannot be casually waved away.